← All trials
NCT03959566
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Jan 31, 2020
- Completion date
- Feb 29, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 75
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Sequella, Inc.Collaborator
- University of California, San FranciscoCollaborator
- Radboud UniversityCollaborator
- Ludwig Maximilians UniversitySponsor investigator
- German Federal Ministry of Education and ResearchCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.